Buy Quality MK-2866 (Ostarine) 10mg | 50 Tablets of the World’s Most Studied SARM for Lean Muscle, Cutting & Bone Density

In January 2025, Veru Inc. announced that Enobosarm (MK-2866/Ostarine) achieved a 71% reduction in lean mass loss when combined with Semaglutide (Wegovy) in a Phase 2b randomized controlled trial — with the 3mg dose group achieving 0% lean mass loss and 100% fat-only weight loss composition. The FDA confirmed 3mg as an acceptable dosage and incremental weight loss as a valid approval endpoint in a September 2025 regulatory meeting. This is the clinical future of muscle preservation science — and it’s built on the same compound you’re looking at right now.

MK-2866 (Ostarine / Enobosarm) isn’t a fringe compound. It has been investigated in 27 clinical trials involving 1,581 men and women — some dosed for up to 3 years — making it the most clinically evaluated SARM in existence. Originally developed by GTx, Inc. in partnership with Merck & Company, it was designed to address one of medicine’s most persistent challenges: preserving lean muscle mass during wasting, aging, cancer, and now — critically — during GLP-1 weight loss therapy. Athletes and physique competitors across the USA, Canada, Germany, France, and the UK have long recognized what the clinical world is now confirming in landmark trials: MK-2866 10mg (50 tablets) for sale is one of the most intelligent compounds available for lean muscle preservation, cutting, and recomposition.

The global anabolic steroids and performance enhancement market continues to expand at a CAGR of over 10% through 2035 — but SARMs represent a distinct and rapidly growing sub-category precisely because they offer tissue-selective anabolic activity without the full androgenic side-effect profile of traditional steroids. And within SARMs, Ostarine MK-2866 consistently ranks as the most researched, most beginner-friendly, and most versatile compound in the entire class.

---

What Is MK-2866 (Ostarine / Enobosarm)?

MK-2866, commonly known as Ostarine and also referred to as Enobosarm, GTx-024, and VERU-024, is a nonsteroidal Selective Androgen Receptor Modulator (SARM). It has been extensively studied in laboratory and clinical research for its tissue-selective activation of androgen receptor (AR) signaling, particularly in skeletal muscle and bone, with reduced androgenic effects in the prostate and reproductive tissues compared to traditional anabolic steroids.

MK-2866 was originally developed by Merck & Company and GTx, Inc. and is under investigation for its potential to treat severe conditions including muscle wasting, cachexia, sarcopenia, and osteoporosis. Clinical studies have suggested that Ostarine has the potential to reduce fasting blood glucose, LDL cholesterol levels, and insulin resistance.

MK-2866 functions as a selective agonist of the androgen receptor. Upon binding to the AR, it modulates transcription of genes involved in muscle protein synthesis and bone remodeling. Following receptor binding, the activated complex undergoes structural changes and translocates to the cell nucleus, where it interacts with androgen response elements (AREs) in genomic DNA — triggering anabolic gene expression specifically in skeletal muscle and bone without the widespread androgenic activity of steroidal compounds.

The 10mg per tablet / 50 tablet format is the ideal research supply for a complete 8–12 week protocol — providing precise oral dosing with the convenience and consistency of pharmaceutical-grade tablet formulation.

---

MK-2866 (Ostarine) 10mg — Full Technical Specification

---

How Does MK-2866 (Ostarine) Work? The Selective Mechanism Explained

Androgens are essential for regulating skeletal muscle mass. However, androgens influence more than just muscle tissue growth — when androgen receptors are indiscriminately activated by compounds such as traditional anabolic steroids, it frequently results in a range of adverse effects in non-target organs including the prostate, skin, and reproductive tissues.

SARMs like Ostarine are engineered to specifically target muscle and bone tissues — potentially enhancing anabolic processes while minimizing effects on reproductive organs and other non-target tissues. MK-2866’s nonsteroidal scaffold features a substituted phenoxy group and an amide linkage that enables high-affinity, tissue-selective binding to the androgen receptor while avoiding the steroidal backbone characteristic of traditional androgens.

Ostarine’s structure offers a unique advantage: it results in increased expression of myogenic regulatory factors — including MyoD and myogenin — in cultured muscle cells, driving the protein synthesis machinery that builds and preserves lean tissue without triggering the full androgenic cascade that causes prostate enlargement, virilization, or cardiovascular strain.

This selectivity is the fundamental reason MK-2866 has spent decades in clinical development for muscle wasting — and why athletes, researchers, and physique competitors have adopted it as the most “clean” anabolic signaling compound available.

---

8 Researched Benefits of MK-2866 (Ostarine) 10mg

1. Lean Muscle Mass Growth — Clinically Confirmed

In a pivotal Phase II randomized, double-blind, placebo-controlled clinical trial, 120 healthy elderly men were given 3mg of Enobosarm daily for 12 weeks. Results showed a statistically significant increase in total lean body mass compared to placebo — with participants also demonstrating improved stair-climbing ability and leg press strength. The study confirmed that MK-2866 can stimulate anabolic activity in muscle tissue without the harmful side effects associated with traditional anabolic steroids.

2. Muscle Preservation During Caloric Deficit — The Cutting Edge

Ostarine prevents muscle breakdown during a caloric deficit, ensuring that the weight lost comes primarily from fat rather than muscle. This makes it extraordinarily valuable during cutting phases, where the typical anabolic response to reduced calories would otherwise create a catabolic environment that strips both fat and lean tissue.

3. 71% Lean Mass Preservation in GLP-1 Weight Loss Protocols (2025 Trial)

In the Phase 2b QUALITY clinical study (January 2025, Veru Inc.), Enobosarm (Ostarine/MK-2866) achieved a 71% reduction in lean mass loss in patients receiving Semaglutide (Wegovy) for weight reduction. The 3mg dose group achieved a weight loss composition of 0% lean mass and 100% fat mass — meaning every pound lost came from fat, not muscle. The FDA confirmed 3mg as an acceptable dosage and incremental weight loss as a valid approval endpoint in September 2025.

4. Bone Density Enhancement

Research into MK-2866’s bone-building properties has demonstrated its ability to stimulate osteoblastic activity — the cellular process responsible for bone matrix formation and mineralization. A study published in the Journal of Geriatric Medicine (2015) investigating the effects of Ostarine on sarcopenia found significant improvements in skeletal muscle mass and supporting bone parameters. MK-2866 also demonstrated efficacy in a 2024 study on estrogen-deficient rats, showing advantage over raloxifene for muscle preservation (J Endocrinol Invest, 2024).

5. Fat Loss & Body Recomposition

A review of studies showed that Ostarine increased lean body mass and decreased fat mass in obese and overweight subjects. In a Phase 2a study, Ostarine was shown to increase lean body mass and decrease body fat percentage simultaneously — confirming its dual-action recomposition capability that makes it uniquely valuable for users who want to build muscle and lose fat at the same time.

6. Cancer Cachexia Reversal — Phase 2 Clinical Evidence

In a Phase II multicenter trial, cancer patients received 1 or 3mg of Enobosarm daily for 113 days. Results showed significant improvement in lean body mass, as well as improvements in stair climb power and walking speed — without the virilizing or estrogenic effects seen with other anabolic agents. Enobosarm has been previously studied in 5 clinical studies involving 968 older normal men and postmenopausal women, as well as older patients with muscle wasting from advanced cancer — establishing one of the most comprehensive human safety databases of any SARM in development.

7. Improved Physical Function & Strength

A randomized, double-blind, placebo-controlled Phase II study demonstrated that oral Enobosarm significantly increased total lean body mass and improved physical function in healthy elderly men and postmenopausal women over 12 weeks — with objective improvements in stair-climbing ability, walking speed, and leg press strength versus placebo.

8. Female-Compatible & Beginner-Friendly

Ostarine is considered one of the most female-tolerable SARMs. Women respond well to Ostarine with minimal virilization risk at conservative dosing (5–10mg daily). Its tissue-selective profile minimizes undesirable effects on the prostate or other non-target organs — and its 24-hour half-life allows for simple once-daily oral dosing without complex injection schedules.

---

Research Benefits Summary Table

---

MK-2866 (Ostarine) Dosage Guide — 10mg Tablets

The 10mg tablet format of MK-2866 is the perfect starting-dose unit — allowing precise titration from a beginner 10mg dose through intermediate 20–25mg protocols using whole or split tablets.

Dosage for Men

Men using MK-2866 for performance and physique goals: 10–20mg per day for 6–8 weeks. 10mg/day supports muscle preservation during a cut; 20mg/day enhances lean mass and strength during a recomposition or bulk.

Dosage for Women

Women using MK-2866 should use 5–10mg per day for 4–6 weeks — using conservative dosing to maintain the compound’s favorable tolerability profile and minimize androgenic activity.

How the 50-Tablet Pack Maps to Your Protocol

For a full 8-week cycle at 20mg/day: 2 packs of 50 tablets provides 56 complete days — ideal coverage.

---

How to Use MK-2866 (Ostarine) 10mg Tablets — Protocol Guide

Step 1 — Take Once Daily
MK-2866 has a half-life of approximately 24 hours, which means it can be taken once per day without splitting the dose to maintain stable plasma levels. This makes it one of the most convenient research compounds available — one tablet per day, same time each day.

Step 2 — With or Without Food
Ostarine tablets can be taken with or without food. If GI sensitivity is a concern, taking with food may improve comfort.

Step 3 — Consistency is Everything
Take at the same time each day — morning dosing is most common for tracking and adherence purposes. Some users prefer evening to align with overnight muscle repair.

Step 4 — Cycle Length
The most common cycle length for MK-2866 is 6–8 weeks, followed by at least an equal amount of time off, during which a PCT can be conducted. While 12-week cycles are possible, 8 weeks is recommended to minimize suppression and maintain the compound’s favorable safety profile.

Step 5 — Follow-Through Protocol
After completing the cycle: take a break equal to the cycle length. If you ran 8 weeks, take 8 weeks off. This approach ensures sufficient recovery time and helps maintain gains effectively.

---

Best Stacking Cycles With MK-2866 10mg

MK-2866 is highly versatile — equally effective as a standalone compound for beginners or as the foundation of a multi-SARM stack for advanced users.

Cutting Stack

Best Ostarine Cutting Stack: Ostarine (10–20mg daily) stacked with Cardarine GW-501516 (10mg daily). The Ostarine will help maintain and even build new muscle in a calorie deficit, while Cardarine supports endurance and keeps training performance high through a different mechanism (PPARδ receptor agonism).

Lean Bulking Stack

Best Ostarine Bulking Stack: Ostarine (10–20mg daily) combined with Ligandrol LGD-4033 (10mg daily). An optional addition is MK-677 (25mg daily) to increase appetite and GH pulse if increased caloric intake becomes a limiting factor.

Recomposition Stack

Recomposition Stack: Ostarine (15–20mg/day) + Ibutamoren MK-677 (20mg/day) for 8 weeks. Ibutamoren helps preserve muscle like Ostarine but through the GH secretagogue axis — combined, they maximize lean mass gains while maintaining caloric efficiency. Gains in the 15 lbs range are achievable with proper training and nutrition.

GLP-1 Muscle Preservation Stack (Cutting-Edge 2025 Protocol)

Based on Veru’s 2025 QUALITY trial results, Enobosarm (MK-2866) is being developed as a next-generation drug that makes GLP-1 weight reduction more tissue-selective — losing fat while preserving lean mass. The PLATEAU trial (planned 2026) will evaluate enobosarm with Tirzepatide (Mounjaro) over 72 weeks for incremental weight loss with muscle preservation.

---

MK-2866 (Ostarine) vs. Other SARMs — The Honest Comparison

*MK-677 is a GH secretagogue, not technically a SARM

Research suggests an Ostarine cycle can offer bodybuilders 6–8 lbs of muscle gain in a cutting cycle while simultaneously achieving 4 lbs of fat loss per month — making it the most versatile and consistent body recomposition SARM available with the most comprehensive clinical evidence base.

---

Post-Cycle Therapy (PCT) After MK-2866 10mg

A post-cycle therapy (PCT) protocol is recommended to help restore natural testosterone levels following Ostarine use. Even though Ostarine does not aromatize, ergogenic dosages can still result in mild testosterone suppression that warrants PCT support.

When PCT is needed: If you are taking 25mg or more per day, or taking MK-2866 for more than 4 weeks, PCT is advisable. Run a SARMs cycle for up to 8 weeks followed by at least an equal amount of time off — during which a full PCT should be conducted.

PCT Start Timing: Begin PCT approximately 3–5 days after the last Ostarine tablet (based on 24-hour half-life allowing rapid clearance) — typically around 3 days after final dose to allow plasma levels to drop before introducing SERM therapy.

---

Clinical Research Timeline — MK-2866 (Enobosarm) 2009 to 2026

---

Possible Side Effects of MK-2866 (Ostarine) 10mg

MK-2866 has one of the most favorable safety profiles of any anabolic-signaling research compound. Full transparency, however, demands the complete picture:

Observed Side Effects

What MK-2866 Does NOT Cause

⚠️ MK-2866 (Ostarine) is prohibited by WADA and USADA and is banned from all professional sports under WADA regulations. Competitive athletes subject to anti-doping testing must avoid this compound. This product is sold strictly for research purposes only in jurisdictions where permitted.

---

FAQs About MK-2866 (Ostarine) 10mg — 50 Tablets

1. What is MK-2866 (Ostarine) and what is it researched for?

MK-2866 (Ostarine / Enobosarm) is a selective androgen receptor modulator (SARM) developed by GTx, Inc. and Merck & Company, originally to treat muscle wasting diseases, sarcopenia, and osteoporosis. It binds selectively to androgen receptors in muscle and bone, promoting anabolic activity while minimizing androgenic effects in non-target organs. Clinical studies have also suggested potential for reducing fasting blood glucose, LDL cholesterol, and insulin resistance.

---

2. Is MK-2866 (Ostarine) a steroid?

No. MK-2866 is a nonsteroidal SARM — it features a fluorinated nonsteroidal small molecule scaffold, not the steroidal backbone of traditional androgens. This structural difference is precisely what allows it to selectively activate androgen receptors in muscle and bone without triggering the full androgenic side effects of steroidal compounds.

---

3. What dose of MK-2866 10mg tablets should I use?

For performance research use in men: 10–20mg per day for 6–8 weeks. 10mg/day (one tablet) supports muscle preservation during cutting; 20mg/day (two tablets) enhances lean mass and strength for recomposition or lean bulking. Women: 5–10mg per day for 4–6 weeks.

---

4. How often should MK-2866 tablets be taken?

Once daily is sufficient. MK-2866 has a 24-hour half-life, meaning one dose per day maintains stable plasma concentrations. Take at the same time each day for maximum consistency — there is no need to split doses throughout the day.

---

5. Does Ostarine (MK-2866) require PCT?

A PCT protocol is recommended following use. At doses of 25mg or more per day, or cycles longer than 4 weeks, PCT is particularly important. At 10–15mg for 4–6 weeks, natural test boosters may be sufficient. At higher doses and longer cycles, Nolvadex (Tamoxifen) 20/20/10/10mg over 4 weeks is the standard PCT approach.

---

6. What is the most important clinical result for MK-2866?

The landmark Phase 2b QUALITY trial (Veru Inc., January 2025) is the most significant recent finding: Enobosarm (MK-2866) achieved a 71% reduction in lean mass loss in patients on Semaglutide (Wegovy), with the 3mg group achieving 0% lean mass and 100% fat mass weight loss composition. The FDA confirmed these findings in a September 2025 regulatory meeting — marking a pivotal moment for Ostarine’s clinical future.

---

7. What are the best stacks for MK-2866 10mg?

For cutting: Ostarine 10–20mg + Cardarine 10mg daily. For bulking: Ostarine 20–25mg + LGD-4033 10mg + optional MK-677 25mg. For recomposition: Ostarine 20mg + MK-677 20mg. MK-2866 works synergistically with nearly every other SARM and non-suppressive performance compound due to its mild nature and tissue-selective mechanism.

---

8. Can women use MK-2866 (Ostarine) 10mg tablets?

Yes — Ostarine is considered one of the more female-tolerable SARMs. Women should use conservative dosing of 5–10mg per day for 4–6 weeks and discontinue immediately at the first sign of androgenic side effects (voice changes, unusual hair growth). Women showed excellent tolerance in clinical studies involving postmenopausal women.

---

9. Does MK-2866 cause water retention or gynecomastia?

No on both counts. MK-2866 does not undergo aromatization to estrogen and exhibits minimal hepatotoxicity — contributing to a favorable safety profile that avoids the estrogenic side effects (water retention, gynecomastia, bloating) that aromatizing compounds routinely cause.

---

10. How long does MK-2866 stay in the system / detection time?

MK-2866 has a 24-hour half-life — it clears blood plasma within approximately 3–5 days. However, WADA testing can detect Ostarine metabolites in urine for significantly longer periods — potentially several weeks — using sensitive LC-MS/MS assays. Competitive athletes under anti-doping jurisdiction must plan accordingly.

---

11. What results can I expect from MK-2866 10mg over 8 weeks?

Research suggests an Ostarine cycle can offer bodybuilders 6–8 lbs of lean muscle gain and approximately 4 lbs of fat loss per month in a cutting cycle — with improved endurance, faster recovery, and increased muscle hardness. Gains are lean and keepable, not water-based bulk. Individual results depend heavily on training consistency, nutrition, and starting body composition.

---

12. Is MK-2866 the right SARM for beginners?

Yes — Ostarine (MK-2866) is one of the most studied and beginner-friendly SARMs available. Its mild suppression, once-daily oral dosing, favorable side-effect profile, and versatility across cutting, bulking, and recomposition protocols make it the standard starting point for anyone new to SARM research. The 10mg tablet format of this product is specifically designed for the precise low-dose entry protocols most appropriate for first-cycle users